WACKER’s ESETEC® Technology Achieves a 12-Fold Higher Yield in the Manufacture of Akari’s Investigational Nomacopan
Jena, May 16, 2022 – The new ESETEC® technology generation developed by WACKER has significantly increased the yield of investigational nomacopan from Akari Therapeutics 12-fold. Nomacopan is the lead asset of Akari. The company develops advanced therapies for autoimmune and inflammatory diseases.För mer information se bifogad pressrelease.